✦ LIBER ✦

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A

✍ Scribed by J. S. POWELL; D. J. NUGENT; J. A. HARRISON; A. SONI; A. LUK; H. STASS; E. GORINA

Book ID: 109152436
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 227 KB
Volume: 6
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2008.02856.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mutation analysis of factor VIII in Kore

Mutation analysis of factor VIII in Korean patients with severe hemophilia A

✍ Chur-Woo You; Hee-Sook Son; Hee Jin Kim; Eui-Jeon Woo; Soon-Ae Kim; Haing-Woon B 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 308 KB

Phosphatidylserine containing liposomes

Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A

✍ Karthik Ramani; Razvan D. Miclea; Vivek S. Purohit; Donald E. Mager; Robert M. S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII act

Tranexamic acid combined with recombinan

Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A

✍ A.-M. HVAS; H. T. SØRENSEN; L. NORENGAARD; K. CHRISTIANSEN; J. INGERSLEV; B. SØR 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 290 KB

Factor XIII combined with recombinant fa

Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A

✍ C. J. REA; J. H. FOLEY; J. INGERSLEV; B. SØRENSEN 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

Safety, pharmacokinetics and efficacy of

Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII – an open label, exploratory, cross-over, phase I/II study

✍ J. SPIRA; O. PLYUSHCH; N. ZOZULYA; R. YATUV; I. DAYAN; A. BLEICHER; M. ROBINSON; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Incidence of inhibitors in patients with

Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor VIII concentrates

✍ Dr. Iise Schwarzinger; Ingrid Pabinger; Christian Korninger; Ferdinand Haschke; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 2 views